Elana Bernstein, MD
Rheumatology · New York, NYNPI 1235334764
Payments from drug & device makers
What this record shows
This record is dominated by consulting fees: $68,146 of the $95,936 with a category attached, or 71.0%. 4 manufacturers reported payments, led by Boehringer Ingelheim at 51.0% of the total. Reporting peaked in 2024 at $37,453 and has fallen 75.8% since, to $9,060 in 2025. Among rheumatology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 69 payments — averaging $1390.38 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Boehringer Ingelheim$49K
- Boehringer Ingelheim International GmbH$46K
- AstraZeneca$895
- E.r. Squibb & Sons, L.L.C.$17
Across 26 payments — averaging $29,278 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Boehringer Ingelheim$500K
- Sanofi US Services Inc.$151K
- AstraZeneca$67K
- Kadmon Corporation LLC$20K
- F. Hoffmann-la Roche AG$15K
- Boehringer Ingelheim International GmbH$6K
- plus $2K from 1 others
What the payments were for
- Consulting fees$68,14671%
- Speaking & faculty fees$4,2804%
- Travel & lodging$22,61924%
- Food & beverage$8911%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Boehringer Ingelheim | 37 | $48,896 |
| Boehringer Ingelheim International GmbH | 27 | $46,127 |
| AstraZeneca | 4 | $895 |
| E.r. Squibb & Sons, L.L.C. | 1 | $17 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$95,936 in reported general payments places this provider in the 90th percentile of 541 rheumatology providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Humira PenAdalimumab | 11 | $136,154 |
| ActemraTocilizumab | 25 | $127,661 |
| Actemra ActpenTocilizumab | 11 | $86,498 |
| Mycophenolate Mofetil | 71 | $17,626 |
| Hydroxychloroquine Sulfate | 15 | $689 |
| MethotrexateMethotrexate Sodium | 18 | $462 |
| Omeprazole | 39 | $458 |
| Nifedipine ErNifedipine | 11 | $212 |
| Diclofenac Sodium | 21 | $196 |
| Duloxetine Hcl | 17 | $141 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 11 | $58 |
| Prednisone | 22 | $48 |
Paid to pharmacies, not to this prescriber.
Other rheumatology in New York
- Laurie GlimcherNew York$3.9M
- Grace WrightNew York$3M
- Sergio SchwartzmanNew York$2.5M
- Allan GibofskyNew York$1.9M
- Petros EfthimiouNew York$791K
- Olga PetrynaNew York$509K
- Danielle PeterselNew York$461K
- Jose ScherNew York$446K
- Jason FallerNew York$357K
- Lindsay LallyNew York$340K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.